{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:39:40Z","timestamp":1777361980694,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsurgicalresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Research"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jss.2021.11.001","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T18:42:37Z","timestamp":1639766557000},"page":"37-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Antigen Receptor T Cells (CAR-T) Effectively Control Tumor Growth in a Colorectal Liver Metastasis Model"],"prefix":"10.1016","volume":"272","author":[{"given":"Louis F.","family":"Chai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4952-1937","authenticated-orcid":false,"given":"John C.","family":"Hardaway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara R.","family":"Heatherton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle P.","family":"O'Connell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason P.","family":"LaPorte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prajna","family":"Guha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikayla C.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin A.","family":"Rabinowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jaroch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan F.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Knight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven C.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jss.2021.11.001_bib0001","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ctrv.2015.06.006","article-title":"Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus","volume":"41","author":"Adam","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jss.2021.11.001_bib0002","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12885-017-3925-x","article-title":"Colorectal cancer liver metastases - a population-based study on incidence, management and survival","volume":"18","author":"Engstrand","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jss.2021.11.001_bib0003","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1186\/1471-2407-14-810","article-title":"Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma","volume":"14","author":"Hackl","year":"2014","journal-title":"BMC Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.jss.2021.11.001_bib0004","first-page":"ii144","article-title":"Treatment of liver metastases of colorectal cancer","volume":"16","author":"Rothbarth","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jss.2021.11.001_bib0005","first-page":"130","article-title":"What is the potential role of hepatic arterial infusion chemo-therapy in the current armamentorium against colorectal cancer","volume":"3","author":"Kanat","year":"2012","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.jss.2021.11.001_bib0006","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1200\/JCO.2007.11.0833","article-title":"Actual 10-year survival after resection of colorectal liver metastases defines cure","volume":"25","author":"Tomlinson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2021.11.001_bib0007","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/hpb.12181","article-title":"Outcomes of extended versus limited indications for patients undergoing a liver resection for colorectal cancer liver metastases","volume":"16","author":"van Dam","year":"2014","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jss.2021.11.001_bib0008","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41417-019-0155-1","article-title":"Challenges in assessing solid tumor responses to immunotherapy","volume":"27","author":"Chai","year":"2019","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jss.2021.11.001_bib0009","series-title":"Timeline of progress: treatment approved","author":"Institute","year":"2020"},{"key":"10.1016\/j.jss.2021.11.001_bib0010","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2021.11.001_bib0011","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2021.11.001_bib0012","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jvir.2018.03.001","article-title":"Regional infusion of chimeric antigen receptor T cells to overcome barriers for solid tumor immunotherapy","volume":"29","author":"Hardaway","year":"2018","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jss.2021.11.001_bib0013","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jss.2021.11.001_bib0014","first-page":"e001097","article-title":"HITM-SURE: phase 1b CAR-T hepatic artery infusion trial for stage iv adenocarcinoma using pressure-enabled drug delivery technology","volume":"6","author":"Katz","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jss.2021.11.001_bib0015","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41417-019-0104-z","article-title":"HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA(+) liver metastases","volume":"27","author":"Katz","year":"2019","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jss.2021.11.001_bib0016","unstructured":"Sorrento Therapeutics, I., CAR-T intraperitoneal infusions for CEA-expressing adenocarcinoma peritoneal metastases or malignant ascites (IPC), The trial number is NCT03682744 and can be accessed at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03682744. My last access date would have been June 2020."},{"key":"10.1016\/j.jss.2021.11.001_bib0017","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/cancers9070092","article-title":"Regional delivery of chimeric antigen receptor (CAR) T-cells for cancer therapy","volume":"9","author":"Sridhar","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jss.2021.11.001_bib0018","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s00270-018-2150-6","article-title":"End-hole versus microvalve infusion catheters in patients undergoing drug-eluting microspheres-TACE for solitary hepatocellular carcinoma tumors: a retrospective analysis","volume":"42","author":"Titano","year":"2019","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jss.2021.11.001_bib0019","doi-asserted-by":"crossref","first-page":"8112","DOI":"10.1158\/1078-0432.CCR-07-4910","article-title":"Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation","volume":"14","author":"Emtage","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jss.2021.11.001_bib0020","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00262-015-1692-6","article-title":"Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T","volume":"64","author":"Burga","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jss.2021.11.001_bib0021","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/hep.20795","article-title":"Conventional liver CD4 T cells are functionally distinct and suppressed by environmental factors","volume":"42","author":"Katz","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jss.2021.11.001_bib0022","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4049\/jimmunol.173.1.230","article-title":"Liver sinusoidal endothelial cells are insufficient to activate T cells","volume":"173","author":"Katz","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.jss.2021.11.001_bib0023","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jvir.2015.01.029","article-title":"The impact of an antireflux catheter on target volume particulate distribution in liver-directed embolotherapy: a pilot study","volume":"26","author":"Pasciak","year":"2015","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jss.2021.11.001_bib0024","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jss.2021.11.001_bib0025","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1113\/jphysiol.1896.sp000596","article-title":"On the absorption of fluids from the connective tissue spaces","volume":"19","author":"Starling","year":"1896","journal-title":"J Physiol"},{"key":"10.1016\/j.jss.2021.11.001_bib0026","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1476-4598-2-12","article-title":"Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer","volume":"2","author":"Duffy","year":"2003","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jss.2021.11.001_bib0027","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ejim.2009.07.009","article-title":"The role of angiogenesis in solid tumours: an overview","volume":"20","author":"Makrilia","year":"2009","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jss.2021.11.001_bib0028","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1146\/annurev-bioeng-112315-031200","article-title":"The lymphatic system in disease processes and cancer progression","volume":"18","author":"Padera","year":"2016","journal-title":"Ann Rev Biomed Eng"},{"issue":"1 Supplement","key":"10.1016\/j.jss.2021.11.001_bib0029","doi-asserted-by":"crossref","first-page":"71.1","DOI":"10.4049\/jimmunol.202.Supp.71.1","article-title":"Regional pressure-enabled drug delivery of anti-PD-1 agent for colorectal liver metastases improves anti-tumor activity without increased hepatic toxicity","volume":"202","author":"Chai","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.jss.2021.11.001_bib0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1245\/s10434-018-7067-4","article-title":"Isolated limb infusion and isolated limb perfusion for melanoma: can the outcomes of these procedures be compared?","volume":"26","author":"Kroon","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jss.2021.11.001_bib0031","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1067\/mtc.2002.120713","article-title":"Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques","volume":"123","author":"Schrump","year":"2002","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4_suppl","key":"10.1016\/j.jss.2021.11.001_bib0032","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1200\/JCO.2020.38.4_suppl.737","article-title":"Comparison of gemcitabine delivery and tumor response in a pressurized pancreatic retrograde venous infusion versus systemic infusion in an orthotopic murine model","volume":"38","author":"Vicente","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2021.11.001_bib0033","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/0267659106073984","article-title":"Isolated lung perfusion for pulmonary metastases, a review and work in progress","volume":"21","author":"Grootenboers","year":"2006","journal-title":"Perfusion"},{"key":"10.1016\/j.jss.2021.11.001_bib0034","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.1984.2.5.498","article-title":"Pharmacologic rationale for regional drug delivery","volume":"2","author":"Collins","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2021.11.001_bib0035","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1200\/JCO.2008.20.1301","article-title":"Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma","volume":"27","author":"Kemeny","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2021.11.001_bib0036","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0959-8049(05)80028-0","article-title":"Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases","volume":"30A","author":"Keilholz","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jss.2021.11.001_bib0037","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41419-018-0278-6","article-title":"CAR-T cells: the long and winding road to solid tumors","volume":"9","author":"D\u2019Aloia","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jss.2021.11.001_bib0038","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.jss.2021.11.001_bib0039","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41388-018-0449-z","article-title":"STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells","volume":"38","author":"Guha","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.jss.2021.11.001_bib0040","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/cgt.2016.19","article-title":"Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases","volume":"23","author":"Thorn","year":"2016","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jss.2021.11.001_bib0041","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/cgt.2016.54","article-title":"Immunosuppression in liver tumors: opening the portal to effective immunotherapy","volume":"24","author":"Guha","year":"2017","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jss.2021.11.001_bib0042","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2021.11.001_bib0043","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jss.2021.11.001_bib0044","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2021.11.001_bib0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 Clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jss.2021.11.001_bib0046","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2021.11.001_bib0047","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jss.2021.11.001_bib0048","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jss.2021.11.001_bib0049","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jss.2021.11.001_bib0050","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jss.2021.11.001_bib0051","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jss.2021.11.001_bib0052","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s10120-018-00909-5","article-title":"Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study","volume":"22","author":"Bang","year":"2019","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.jss.2021.11.001_bib0053","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1200\/JCO.19.00538","article-title":"Nivolumab alone and with Ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg\/kg plus Ipilimumab 3 mg\/kg expansion cohort results","volume":"37","author":"Sharma","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2021.11.001_bib0054","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/j.jss.2021.11.001_bib0055","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1158\/1078-0432.CCR-21-0136","article-title":"Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion","volume":"27","author":"Conforti","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jss.2021.11.001_bib0056","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jss.2021.11.001_bib0057","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s13238-019-0643-y","article-title":"Chimeric antigen receptor T (CAR-T) cells expanded with IL-7\/IL-15 mediate superior antitumor effects","volume":"10","author":"Zhou","year":"2019","journal-title":"Protein Cell"}],"container-title":["Journal of Surgical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480421006958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480421006958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T14:55:03Z","timestamp":1758380103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022480421006958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":57,"alternative-id":["S0022480421006958"],"URL":"https:\/\/doi.org\/10.1016\/j.jss.2021.11.001","relation":{},"ISSN":["0022-4804"],"issn-type":[{"value":"0022-4804","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antigen Receptor T Cells (CAR-T) Effectively Control Tumor Growth in a Colorectal Liver Metastasis Model","name":"articletitle","label":"Article Title"},{"value":"Journal of Surgical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jss.2021.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}